Amphastar Pharmaceuticals executive Zhou Rong sold 3,187 shares at $23.63 per share, leaving 169,203 shares owned after the transaction. The transaction gives investors a specific view of the executive’s remaining Amphastar Pharmaceuticals shareholding and the price attached to the sale, dated 2026-09-02.
Key Highlights
- Zhou Rong serves as Amphastar Pharmaceuticals’ senior executive vice president of the production center.
- The transaction took place on 2 September 2026 under transaction code S.
- Zhou Rong’s post-transaction holding was 169,203 Amphastar Pharmaceuticals shares.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) executive Zhou Rong sold 3,187 shares at $23.63 per share. The transaction left Rong with 169,203 shares of Amphastar Pharmaceuticals.
Zhou Rong’s Shareholding After the Sale
Zhou Rong is the company’s senior executive vice president of the production center. The sale occurred on 2 September 2026. The transaction carried code S. Amphastar Pharmaceuticals’ executive share transaction involved 3,187 shares priced at $23.63 each. Rong’s remaining ownership after the sale was 169,203 shares.
FAQs
Q: How many Amphastar Pharmaceuticals shares did Zhou Rong sell?
A: Zhou Rong sold 3,187 Amphastar Pharmaceuticals shares in the reported transaction. The Form 4 filing states that the shares were sold at $23.63 each on 2 September 2026.
Q: How many Amphastar Pharmaceuticals shares does Zhou Rong still own?
A: Zhou Rong owned 169,203 Amphastar Pharmaceuticals shares after the transaction. Rong serves as senior executive vice president of the production center.
Q: What was the price of Zhou Rong’s Amphastar Pharmaceuticals share sale?
A: The filing reports a sale price of $23.63 per Amphastar Pharmaceuticals share. Zhou Rong’s transaction involved 3,187 shares and took place on 2 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.